news

EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines

Posted: 13 May 2015 |

EIB has reaffirmed its commitment to respond to the Ebola pandemic by providing a EUR 50m loan to Bavarian Nordic for accelerated development of a vaccine…

The European Investment Bank (EIB) has reaffirmed its commitment to respond to the Ebola pandemic.

eib-ebola

The Bank has provided a EUR 50 million loan to Bavarian Nordic for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

EIB is sending a clear signal that the international community cannot abandon West Africa

EIB Vice-President Jonathan Taylor stated, “We are pleased to be partnering with Bavarian Nordic in this breakthrough operation, as it enables the EU bank to address the high unmet medical need caused by a pandemic such as Ebola. The European Investment Bank sends a clear signal that the international community cannot abandon West Africa at this time of need and must continue to demonstrate firm engagement. We are also delighted that we are supporting the first market entry of a European company into the cancer treatment vaccine arena. Projects such as this strengthen the competitiveness and boost the innovative capacity of European health-related industries and businesses.”

President and CEO of Bavarian Nordic Paul Chaplin said, “The rapid development and manufacture of an Ebola vaccine would not be possible without public investment, and we are thankful for the commitment from the EIB to help us in our endeavour to provide an effective vaccine in response to current and future epidemics. The EIB loan provides financial flexibility for our company to advance the development of novel vaccine candidates utilising our modern technology, MVA-BN®, a robust and adaptable vaccine platform suitable for addressing a wide variety of infectious diseases and cancers.”

EIB finance will back the production of batch materials needed for clinical trials

Bavarian Nordic’s research activities supported by the EIB include the preclinical and clinical development of several novel vaccines in the infectious disease and oncology areas. EIB finance will also back the production of the batch materials needed to conduct the clinical trials. These are particularly relevant for the Ebola vaccine, as the manufacture of two million doses is necessary for the second phase of the clinical trials.

Preclinical trials of the Ebola vaccine with the US National Institute of Allergy and Infectious Diseases (NIAID) have shown 100% protection against the highly virulent Ebola Zaire strain, which is responsible for the recent outbreak. The EIB has already shown its commitment to tackling the Ebola crisis in West Africa through the provision of much-needed finance. Along with others, the Bank provided a loan of nearly EUR 20 million to support upgrading of the runway and safety equipment at Monrovia airport, a key gateway for aid workers and humanitarian assistance in Liberia.

The prostate cancer vaccine (PROSTVAC®) is Bavarian Nordic’s leading targeted immunotherapy candidate. It has the potential to revolutionise prostate cancer therapy, as it demonstrated in the clinical trials a higher efficacy and, more importantly, lower side effects than other treatments such as chemotherapy. These encouraging results have led to the signature of a lucrative licensing agreement providing for the payment of significant milestones for having access to this vaccine on an exclusive basis.

Related organisations

Related diseases & conditions